Patents Examined by Erin M Bowers
-
Patent number: 12285470Abstract: Tie present invention relates to compositions and methods of influencing autophagy by modulating TRIM (tripartite motif containing) proteins, especially TRIM 8, TRIM: 10, TRIM 16, TRIM 19 and/or TRIM 51 (preferably TRIM 16} and galectins, especially galectins 3 m order to influence autophagy and treat a number of disease states and/or conditions which are mediated and/or influenced by autophagy, including inflammatory disease states and/or conditions, including a microbial infection such as a Mycobacterium infection, among numerous others, an inflammatory disorder, a lysosomal, storage disorder, an immune disorder, a neurodegenerative disorder and a cancer.Type: GrantFiled: July 31, 2017Date of Patent: April 29, 2025Assignee: UNM RAINFOREST INNOVATIONSInventor: Vojo Deretic
-
Patent number: 12274720Abstract: Provided herein are methods for preventing or treating diseases, said methods comprising (i) inhibiting entry of bacteriophages and/or component(s) thereof into microbiota, bodily fluid(s) or tissue(s) of the mammals and/or (ii) inactivating or modifying bacteriophages and/or component(s) thereof present in microbiota, bodily fluid(s) or tissues of the mammals and/or (iii) inactivating or modifying bacteriophages and/or component(s) thereof in one or more of food, drinking water, water for washing, water for air humidification, air, or habitat object of the mammals.Type: GrantFiled: April 20, 2018Date of Patent: April 15, 2025Inventors: Viktor Veniaminovich Tets, Georgy Viktorovich Tets
-
Patent number: 12276667Abstract: Disclosed herein are methods for solubilizing and isolating nuclear proteins from cells.Type: GrantFiled: May 21, 2019Date of Patent: April 15, 2025Assignee: Altius Institute for Biomedical SciencesInventors: Alexander Federation, John Stamatoyannopoulos
-
Patent number: 12258589Abstract: Provided is a glycated hemoglobin oxidase with small measurement error or without deviation of the measured value from the true value regarding a sample containing glycated abnormal hemoglobin. Provided are a glycated hemoglobin oxidase comprising an amino acid sequence in which the amino acid at the position corresponding to position 113, 109, 106, or 102 of the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid other than a positively-charged amino acid, such as glutamic acid, alanine, or aspartic acid as well as a method and a reagent kit for measurement of glycated hemoglobin using such glycated hemoglobin oxidase. The glycated hemoglobin is capable of reacting with various genotypes and enables highly accurate measurement of glycated hemoglobin in a sample containing glycated abnormal hemoglobin.Type: GrantFiled: August 31, 2018Date of Patent: March 25, 2025Assignee: Kikkoman CorporationInventor: Atsushi Ichiyanagi
-
Patent number: 12258547Abstract: A cell culture plate includes one or more cell culture well(s) including at least one barrier for dividing the well into at least two compartments, wherein the barrier includes nanofibrillar cellulose hydrogel, and a method for the preparation thereof. A method for detecting a substance is also disclosed.Type: GrantFiled: May 19, 2020Date of Patent: March 25, 2025Assignee: UPM-KYMMENE CORPORATIONInventors: Markus Nuopponen, Lauri Paasonen, Marika Mannerström, Tuula Heinonen, Tarja Toimela
-
Patent number: 12246041Abstract: A medicament is provided including, for example, a dried particulate mixture of decellularized amniotic material and a powdered, lyophilized mixture of cervical mucus plug. The medicament may be useful in treating infectious disease, for example, viral diseases, in promoting repair of tissue and halting disease progression.Type: GrantFiled: May 12, 2023Date of Patent: March 11, 2025Assignee: ANICELL BIOTECH, LLCInventors: Brandon Ames, Christopher A. Bradley, Tammi Epp
-
Patent number: 12235217Abstract: A method for analyzing a sample includes introducing the sample into a vessel including a cation-exchange resin, where the cation-exchange resin has a high affinity to one or more interferent species in the sample, directing the sample through the cation-exchange resin to thereby capture one or more interference species in the cation-exchange resin to purify the sample, and releasing the purified sample from the vessel. Additionally, a method for analyzing a sample includes receiving an image depicting a diagnostic test region and a color reference chart, converting a test region image portion of the image to an analytical color space, determining first and second coordinate values characterizing the test region image portion in the analytical color space, and providing a quantitative measurement of an analyte of interest in the sample based on the first and/or second coordinate values and a predictive formula based on the color reference chart.Type: GrantFiled: November 13, 2020Date of Patent: February 25, 2025Assignee: Scanwell Health, Inc.Inventors: Yunyuan Vivian Wang, Aaron Alexander Rowe, Hui-Ling Koh, Stephen L. Chen, K C Chen
-
Patent number: 12235260Abstract: The present disclosure relates to systems and methods for analysis of proteins, more in particular to nanopore systems, devices and methods for single-molecule protein analysis and sequencing. Provided is a method for translocating a target protein through a nanopore, the nanopore being comprised in a membrane separating a fluidic chamber of a nanopore system into a cis side and a trans side, comprising: (a) allowing a protein translocase in solution to capture and form a complex with the target protein to be translocated; (b) contacting the translocase-target protein complex with the cis side of the nanopore and allowing for translocation of the target protein to the trans side; wherein the nanopore system has a cis to trans electro-osmotic force (EOF) resulting from a large net ionic current flow cis-to-trans relative to the total ionic current flow, so that the target protein is captured in the nanopore with on top of the nanopore the translocase controlling the translocation.Type: GrantFiled: December 22, 2023Date of Patent: February 25, 2025Assignees: Rijksuniversiteit Groningen, Portal Biotech LimitedInventors: Giovanni Maglia, Shengli Zhang, Andrew Heron
-
Patent number: 12234499Abstract: Provided herein are compositions, methods, systems and/or kits for detection of bacteria expressing enzymes that confer resistance to antimicrobial agents. Certain embodiments of the compositions, methods, systems and/or kits of the present disclosure are related to detection of carbapenemase-producing gram negative bacteria. Certain embodiments of the compositions, methods, systems and/or kits of the present disclosure are related to detection of Ambler Class A, B and/or D carbapenemase-producing enteric and non-fermenting gram negative rod bacteria.Type: GrantFiled: March 25, 2022Date of Patent: February 25, 2025Assignee: BECTON, DICKINSON AND COMPANYInventors: William B. Brasso, David J. Turner, Susan M. Kircher, Fatimah Alrashidi-Brooks
-
Patent number: 12173332Abstract: A new mutant of D-amino acid transaminase, based on supercomputing-assisted technology, belongs to the fields of computational biology, computer-aided design, and enzyme engineering technology, and specifically relates to mutants of D-amino acid transaminase obtained based on supercomputing-assisted technology and applications thereof. Compared to the wild-type enzyme, the aforementioned mutant of D-amino acid transaminase exhibits a half-life (t1/2) of over 12 hours at 40° C., while it is only 8.8 minutes for the wild-type D-amino acid transaminase. The half-inactivation temperature (T5015) of the mutant is 45.3° C., approximately 5.4° C. higher than that of the wild-type D-amino acid transaminase. This substantially enhances its thermal stability, enzymatic activity, etc., effectively broadening its application fields and scope. The mutant has a wide range of industrial applications and thus holds substantial practical value.Type: GrantFiled: July 26, 2023Date of Patent: December 24, 2024Assignee: SHANDONG COMPUTER SCIENCE CENTER (NATIONAL SUPERCOMPUTER CENTER IN JINAN)Inventors: Xin Wang, Ming Yang, Xiaoming Wu, Fuqiang Wang, Yan Liang, Zhenya Chen, Chao Mu
-
Patent number: 12173049Abstract: Provided herein, inter alia, are compositions and methods for culturing mammalian cells. In certain aspects, the composition is a medium containing one or more of a lithium ion source, one or more fatty acids, and/or ethanol. Use of any of the cell culture media described herein to culture cells that have been genetically engineered to produce one or more recombinant polypeptides (for example, antibodies) can result in increased titers, a more favorable glycosylation profile, and/or modulated (e.g. decreased) amounts of high and low molecular weight species, and/or modulated (e.g. decreased) amounts of acidic or basic charge variants, compared to cells cultured in a medium that does not contain one or more of a lithium ion source, one or more fatty acids, and/or ethanol.Type: GrantFiled: June 19, 2020Date of Patent: December 24, 2024Assignee: La Jolla Biologics, Inc.Inventors: Christopher T. Leber, Michael W. Y. Shen, Yiwen Tao, Hugh Eugene Murray, IV
-
Patent number: 12168041Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.Type: GrantFiled: March 24, 2020Date of Patent: December 17, 2024Assignee: Takeda Pharmaceutical Company LimitedInventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias
-
Patent number: 12121569Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.Type: GrantFiled: January 18, 2022Date of Patent: October 22, 2024Assignee: Takeda Pharmaceutical Company LimitedInventors: Gaozhong Zhu, Kris Lowe, Zahra Shahrokh, James Christian, Richard Fahrner, Jing Pan, Teresa Leah Wright, Pericles Calias
-
Patent number: 12084650Abstract: Provided is a composition for preserving cell-free nucleic acids and/or cells in a biological sample and methods for use thereof. The composition comprises at least one volume excluding polymer, at least one osmotic agent and at least one enzyme inhibitor. The composition optionally further comprises at least one metabolic inhibitor. Further, provided is a kit comprising the composition, preferably in a blood collection tube, or the components of the composition.Type: GrantFiled: April 20, 2023Date of Patent: September 10, 2024Assignee: Norgen Biotek Corp.Inventors: Taha Alexander Haj-Ahmad, Yousef Haj-Ahmad
-
Patent number: 12084677Abstract: Described herein are methods of recellularizing an organ or tissue matrix.Type: GrantFiled: July 6, 2022Date of Patent: September 10, 2024Assignee: Regents of the University of MinnesotaInventors: Doris Taylor, Stefan M. Kren
-
Patent number: 12048722Abstract: Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures.Type: GrantFiled: July 29, 2022Date of Patent: July 30, 2024Assignee: Solarea Bio, Inc.Inventors: Gerardo V. Toledo, Maria Juliana Soto-Giron, Jinwoo Kim, Julie E. Button, Eric Michael Schott
-
Patent number: 12024704Abstract: Compositions including metal nano- and/or micro-particles in solution with photosynthetic bioproduct producing microorganisms. These light harvesting complexes increase growth rates and photosynthetic efficiency of the constituent microorganisms, reducing the light required for a specific production level, or increases production for a specific light level. Compositions including zero-valent iron nanoparticles (nZVIs) in solution with photosynthetic bioproduct producing microorganisms. The nZVIs cause increased growth, lipid production and fatty acid production.Type: GrantFiled: December 12, 2019Date of Patent: July 2, 2024Assignee: Morgan State UniversityInventors: Viji Sitther, Somayeh Fathabad
-
Patent number: 12023412Abstract: Disclosed is a dissolvable, gel-forming film, and methods for its use, comprising a water-soluble cellulose ether, a hydrophilic rheological modifying agent, and an active proteolytic enzyme or other drug substance. The gel-forming film has a water content of less than 15% w/w and is capable of forming a hydrogel when contacted with water or other aqueous medium. The disclosed films achieve delivery of stable proteolytic enzymes to the desired site of action in a manner that provides uniform delivery of the enzymes.Type: GrantFiled: August 22, 2022Date of Patent: July 2, 2024Assignee: SMITH & NEPHEW, INC.Inventors: Lei Shi, Aleksa Jovanovic, Dennis Carson
-
Patent number: 12016907Abstract: Disclosed is a hydrogel comprising a hydrophilic gelling agent that includes a nonionic cellulose ether, and active thermolysin, wherein the proteolytic activity of the thermolysin does not decrease by more than 20% when stored at room temperature for 6 months.Type: GrantFiled: August 15, 2022Date of Patent: June 25, 2024Assignee: SMITH & NEPHEW, INC.Inventors: Lei Shi, Aleksa Jovanovic, Dennis Carson
-
Patent number: 12011476Abstract: The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.Type: GrantFiled: May 14, 2020Date of Patent: June 18, 2024Assignee: The University of Vermont and State Agricultural CollegeInventors: Yvonne M. Janssen-Heininger, Vikas Anathy